The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage
1Universitätsklinikum Essen, Klinik für Gastroenterologie und Hepatologie, Essen, Germany.
Insights
Early detection of hepatocellular carcinoma (HCC) is improved by combining AFP, AFP-L3, and DCP biomarkers. The GALAD score demonstrated superior specificity and sensitivity for diagnosing HCC, even in AFP-negative cases.
Area of Science:
- Hepatology
- Oncology
- Biomarker Discovery
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death, particularly in patients with cirrhosis.
- Current screening methods often fail to detect HCC at early, treatable stages.
- Advanced stage diagnosis limits treatment options for most HCC patients.
Purpose of the Study:
- To validate the diagnostic performance of individual biomarkers: alpha-fetoprotein (AFP), AFP-L3, and des-gamma-carboxy prothrombin (DCP).
- To assess the added benefit of combining these biomarkers and a novel algorithm, GALAD, for HCC detection.
- To evaluate the efficacy of the GALAD score in identifying early-stage HCC.
Main Methods:
- Retrospective analysis of 285 newly diagnosed HCC patients and 402 controls with chronic liver disease.
- Measurement of AFP, AFP-L3, and DCP using the µTASWako i30 automated immunoanalyzer.
- Validation of diagnostic performance using single markers, marker combinations, and the GALAD algorithm (gender, age, AFP, AFP-L3, DCP).
Main Results:
- Individual biomarkers (AFP, AFP-L3, DCP) showed comparable sensitivity and specificity for HCC detection.
- The combination of all biomarkers yielded high sensitivity but reduced specificity.
- The GALAD score achieved superior specificity (93.3%) and sensitivity (85.6%), with the highest AUROC (0.9242) for early-stage HCC (BCLC 0/A).
Conclusions:
- The GALAD score significantly improves the detection of early-stage HCC compared to individual biomarkers or their simple combination.
- This biomarker panel and algorithm demonstrate high diagnostic accuracy, even in cases where AFP is negative.
- The findings support the clinical utility of the GALAD score for earlier and more accurate HCC diagnosis.
Abstract:
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of death in cirrhotic patients worldwide. The detection rate for early stage HCC remains low despite screening programs. Thus, the majority of HCC cases are detected at advanced tumor stages with limited treatment options. To facilitate earlier diagnosis, this study aims to validate the added benefit of the combination of AFP, the novel biomarkers AFP-L3, DCP, and an associated novel diagnostic algorithm called GALAD. Material and methods: Between 2007 and 2008 and from 2010 to 2012, 285 patients newly diagnosed with HCC and 402 control patients suffering from chronic liver disease were enrolled. AFP, AFP-L3, and DCP were measured using the µTASWako i30 automated immunoanalyzer. The diagnostic performance of biomarkers was measured as single parameters and in a logistic regression model. Furthermore, a diagnostic algorithm (GALAD) based on gender, age, and the biomarkers mentioned above was validated. Results: AFP, AFP-L3, and DCP showed comparable sensitivities and specifities for HCC detection. The combination of all biomarkers had the highest sensitivity with decreased specificity. In contrast, utilization of the biomarker-based GALAD score resulted in a superior specificity of 93.3 % and sensitivity of 85.6 %. In the scenario of BCLC 0/A stage HCC, the GALAD algorithm provided the highest overall AUROC with 0.9242, which was superior to any other marker combination. Conclusions: We could demonstrate in our cohort the superior detection of early stage HCC with the combined use of the respective biomarkers and in particular GALAD even in AFP-negative tumors.
